Comparative study of biological glues: cryoprecipitate glue, two-component fibrin sealant, and "French" glue. 1995

S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
Maimonides Medical Center, Brooklyn, New York 11219, USA.

BACKGROUND Although biological glues have been used clinically in cardiovascular operations, there are no comprehensive comparative studies to help clinicians select one glue over another. In this study we determined the efficacy in controlling suture line and surface bleeding and the biophysical properties of cryoprecipitate glue, two-component fibrin sealant, and "French" glue containing gelatin-resorcinol-formaldehyde-glutaraldehyde (GRFG). METHODS Twenty-four dogs underwent a standardized atriotomy and aortotomy; the incisions were closed with interrupted 3-0 polypropylene sutures placed 3 mm apart. All dogs had a 3- by 3-cm area of the anterior wall of the right ventricle abraded until bleeding occurred. The animals were randomly allocated into four groups: in group 1 (n = 6) bleeding from the suture lines and from the epicardium was treated with cryoprecipitate glue; in group 2 (n = 6) bleeding was treated with two-component fibrin sealant; group 3 (n = 6) was treated with GRFG glue; group 4 (n = 6) was the untreated control group. The glues were also evaluated with regard to histomorphology, tensile strength, and virology. RESULTS The cryoprecipitate glue and the two-component fibrin sealant glue were equally effective in controlling bleeding from the aortic and atrial suture lines. Although the GRFG glue slowed bleeding significantly at both sites compared to baseline, it did not provide total control. The control group required additional sutures to control bleeding. The cryoprecipitate glue and the two-component fibrin sealant provided a satisfactory clot in 3 to 4 seconds on the epicardium, whereas the GRFG glue generated a poor clot. There were minimal adhesions in the subpericardial space in the cryoprecipitate and the two-component fibrin sealant groups, whereas moderate-to-dense adhesions were present in the GRFG glue group at 6 weeks. The two-component fibrin sealant was completely reabsorbed by 10 days, but cryoprecipitate and GRFG glues were still present. On histologic examination, both fibrin glues exhibited minimal tissue reaction; in contrast, extensive fibroblastic proliferation was caused by the GRFG glue. The two-component and GRFG glues had outstanding adhesive property; in contrast, the cryoprecipitate glue did not show any adhesive power. The GRFG glue had a significantly greater tensile strength than the two-component fibrin sealant. Random samples from both cryoprecipitate and the two-component fibrin glue were free of hepatitis and retrovirus. CONCLUSIONS The GRFG glue should be used as a tissue reinforcer; the two-component fibrin sealer is preferable when hemostatic action must be accompanied with mechanical barrier; and finally, the cryoprecipitate glue can be used when hemostatic action is the only requirement.

UI MeSH Term Description Entries
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012118 Resorcinols A water-soluble crystalline benzene-1,3-diol (resorcinol) and its derivatives. m-Dihydroxybenzenes,meta-Dihydroxybenzenes,m Dihydroxybenzenes,meta Dihydroxybenzenes
D002921 Cicatrix The fibrous tissue that replaces normal tissue during the process of WOUND HEALING. Scars,Cicatrization,Scar,Scarring
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005557 Formaldehyde A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons. In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. Formaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717) Formalin,Formol,Methanal,Oxomethane
D005780 Gelatin A product formed from skin, white connective tissue, or bone COLLAGEN. It is used as a protein food adjuvant, plasma substitute, hemostatic, suspending agent in pharmaceutical preparations, and in the manufacturing of capsules and suppositories. Gelafusal

Related Publications

S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
October 2005, Transfusion medicine (Oxford, England),
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
March 1991, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
July 1996, The Annals of thoracic surgery,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
October 1990, Transfusion,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
August 2013, Gastrointestinal endoscopy,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
January 1989, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
October 1990, Fertility and sterility,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
January 2003, Journal of reconstructive microsurgery,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
March 1995, Journal of reconstructive microsurgery,
S Basu, and C P Marini, and F G Bauman, and D Shirazian, and P Damiani, and R Robertazzi, and I J Jacobowitz, and A Acinapura, and J N Cunningham
January 2009, Microsurgery,
Copied contents to your clipboard!